Neovir, 250 mg/2 ml 2 ml 5 pcs

Immunostimulatory drug. It has antiviral activity against DNA- and RNA-genomic viruses. It has a pronounced antichlamydial effect. The activity of the drug is connected with its ability to induce high titers of endogenous interferon in the body, especially of interferon alpha.

Intravenous administration of Neovir at a dose of 250 mg is equivalent to administration of 6-9 million IU of recombinant interferon alfa according to detected serum concentrations of interferon.

Neovir activates bone marrow stem cells, T-lymphocytes and macrophages. It shows immunomodulatory activity by normalizing the balance between subpopulations of T-helper and T-suppressor cells. In some diseases Neovir can decrease production of tumor necrosis factor (HIV-infection, herpes) and activate natural killer cells (in case of tumor diseases). Significantly increases the activity of polymorphonuclear leukocytes.

In HIV-infection Neovir has immunomodulating effect: it increases absorption activity of blood serum, increases ability of leukocytes to synthesize interferon alpha, stimulates formation of reactive oxygen species by phagocytes.

The peak of interferon activity in blood and tissues occurs several hours after administration of Neovir and persists for 16-20 hours.

Pharmacokinetics

Eabsorption

When administered in m/v the bioavailability of Neovir is more than 90%. After administration of Neovir at a dose of 100-500 mg, C_max in plasma is reached after 15-30 minutes and is 8.3 mcg/ml. After 5 h only minor concentrations of the active substance are detected, and after 6 h the drug is undetectable in plasma.

In 15-30 minutes after Neovir administration, serum interferon titers in plasma begin to increase. Two peaks of interferon in plasma were detected: 70 IU/ml after 1.5-2 hours and 110 IU/ml after 8-10 hours, after which they begin to decrease. After 24 hours, the concentration of serum interferons remains quite high, and returns to the initial values after 46-48 hours.

Metabolism and excretion

It is not metabolized. T_1/2 is 1 h. It is excreted unchanged by the kidneys.

Indications

Chlamydia, HIV infection, Urethritis, Prostatitis, Inflammation of female genitalia, Flu, Herpes, Cytomegalovirus infection, Hepatitis, Cancer

As immunostimulating agent in combined therapy: prevention and treatment of flu and other acute respiratory diseases (including against immunodeficiency conditions.against the background of immunodeficiency states); infections caused by Herpes simplex virus types 1 and 2 and Varicella zoster virus (including. persons with immune system disorders);

cytomegalovirus infection in persons with immunodeficiencies;

radiation immunodeficiency; treatment of HIV infection;

encephalitis and encephalomyelitis of viral etiology; acute and chronic hepatitis B and C;

urethritis, epididymitis, prostatitis, cervicitis and salpingitis of chlamydial etiology;

venereal lymphogranuloma;

cancer;

multiple sclerosis;

candidiasis of the skin and mucous membranes.

Active ingredient

Sodium oxodihydroacridinyl acetate

Composition

1 ml of the solution contains:

Active ingredient:

Oxodihydroacridinylacetate sodium (Neovir®) – 125 mg

Excipients:

sodium citrate – 2.5 mg;

citric acid monohydrate – 0.5-1.5 mg (to pH 7.5-8.3);

water for injection – to 1 ml.

How to take, the dosage

The solution for injection is given by injection/m and the single dose is 250 mg (1 ampoule) or 4-6 mg/kg body weight. If necessary, the single dose of Neovir can be increased to 500 mg.

The course of treatment, if there are no special indications, consists of 5-7 single-dose intravenous injections with an interval of 48 hours. The course dose depends on the clinical picture. Course duration is 8-12 days. When prolonged and prophylactic use the interval between injections of Neovir is 3-7 days.

In case of HIV infection the solution for injection is used as part of combined therapy. A course of treatment consists of 10 intravenous injections of 250 mg with an interval of 48 hours between injections. After the course of therapy, there is a break of 2 months. The number of repeated courses is not limited.

Interaction

In the course of clinical trials and use of the drug in clinical practice there have been no cases of incompatibility or potentiation of the drug in interaction with other medicinal products.

There is no information about physicochemical incompatibility of Neovir with other medicinal products.

Special Instructions

In case of poor tolerance or pain at the site of injection, it is recommended that Neovir be given together with 2 ml of 0.25-0.5% novocaine solution.

Contraindications

Hypersensitivity, pregnancy, breastfeeding.

Perhaps with caution in elderly patients.

Side effects

General reactions: subfebrile fever, allergic reactions.

Local reactions: local, quickly resolving soreness at the site of injection.

Overdose

There are no data on overdose of Neovir.

Pregnancy use

The drug is contraindicated in pregnancy and during lactation (breast-feeding).